Introduction {#s1}
============

Phosphoinositide 3-kinases (PI3Ks) control essential functions in cellular activation, development and differentiation through generation of phosphatidylinositol (3,4,5)-trisphosphate (PIP~3~) ([@B1]). In lymphocytes, the PI3K complex is made up of a heterodimer consisting of a catalytic subunit (p110δ) and a regulatory subunit (p85α) that are encoded by the *PIK3CD* and *PIK3R1* genes, respectively ([@B1]). Heterozygous gain-of-function mutations in *PIK3CD* lead to constitutive activation of the PI3K pathway and cause activated PI3K delta syndrome type 1 (APDS1); similarly, heterozygous *PIK3R1* mutations that affect interaction of p85α with p110δ also lead to constitutive activation of PI3K and cause APDS2 ([@B2]--[@B7]). The clinical presentation of these primary immunodeficiencies (PIDs) may include recurrent upper respiratory tract infections often leading to bronchiectasis, humoral immunodeficiency with elevated IgM, diffuse lymphadenopathy, Epstein Barr virus, and/or cytomegalovirus viremia, and an increased risk of lymphoma ([@B8], [@B9]). In addition, mutations in the donor splice site in intron 11 of *PIK3R1*^Δ*434*\ \_*475*^, resulting in exclusion of exon 11 from the cDNA, cause APDS2, *s*hort stature-*h*yperextensibility of joints-*o*cular depression-*R*ieger anomaly-*t*eething delay (SHORT) syndrome, or a combination of the two ([@B10]).

We describe a female with APDS2 manifesting with short stature, diffuse lymphadenopathy, recurrent upper respiratory tract infections, elevated IgM and disseminated toxoplasmosis who gave birth to a genetically affected daughter with severe, congenital toxoplasmosis.

Case Report
-----------

The patient was born to non-consanguineous healthy parents of Hispanic and East Asian descent. In early childhood, she was diagnosed with recurrent sinopulmonary and otitis infections. Due to persistent diffuse lymphadenopathy since age 5, she underwent multiple lymph node and bone marrow biopsies that were negative for malignancy. She also suffered from multiple episodes of Herpes Simplex oral infection and genital warts, which required electrosurgical excision of precancerous lesions. At the age of 40, she complained of painful cervical lymphadenopathy and was diagnosed with toxoplasmosis based on positive IgM serology results. An ophthalmological and MRI exam were normal. She was treated for 2 weeks with an unknown agent(s) with the presumption that her infection was cured. Then, she immigrated to Rhode Island (USA), where she gave birth to a female baby at 37 weeks gestation. There were concerns for craniosyntosis, occasional episodes of staring and myoclonic jerks that led to a brain CT scan at 3 months of age that showed marked hydrocephalus, enlarged lateral and third ventricles, and extensive cerebral atrophy ([Figure 1A](#F1){ref-type="fig"}). There were widespread calcifications at the gray-white matter interface and in the basal ganglia. The clinical, laboratory and radiologic features were consistent with a congenitally acquired infection. Tests for CMV, HIV, HSV and syphilis were negative while serologic tests for *Toxoplasma gondii* were positive (IgG was 1:512, IgM was positive by the ISAGA method, IgA antibodies were negative; Palo Alto Toxoplasma Serology Laboratory). *T. gondii* PCR assays of the blood and CSF were negative. A dried blood spot from the newborn screen was positive when retrospectively tested for *T. gondii* IgM antibodies at Massachusetts Department of Health.

![Clinical and laboratory features in mother and daughter with Toxoplasmosis and APDS2. **(A)** Brain CT in the patient\'s daughter at 3 months of age, showing marked hydrocephalus with enlarged lateral and third ventricles, profound brain atrophy and basal ganglia calcifications. **(B)** Chromatogram demonstrating heterozygosity for the c.1425+1g \> a at the *PIK3R1* locus in the patient and her daughter. **(C)** Analysis of phospho-S6 in CD20^+^ cells from a healthy control, the mother, and the daughter at resting conditions (top) and upon *in vitro* activation with anti-IgM (bottom).](fimmu-10-00077-g0001){#F1}

The child met criteria for congenital toxoplasmosis ([@B11]) and was treated with oral pyrimethamine, sulfadiazine and leucovorin. During the following year, the child had refractory seizures despite treatment with topiramate, levetiracetam and clonazepam, her microcephaly progressed to \<1st percentile, and static encephalopathy with poor feeding necessitated a gastrostomy tube. The anti-toxoplasma IgG titer decreased while on antimicrobial therapy and was undetectable by 36 weeks of treatment. Two months after completion of a 1-year course of anti-parasitic therapy, repeat anti-*Toxoplasma* IgG testing showed a rebound to a titer of 1:8,000. At 2 years of age, repeat anti-*Toxoplasma* IgG (1:3,072) and IgM (7.6, normal \< 2.0) levels remained elevated. She has elevated serum IgG (1,399 mg/dL) and IgM (215 mg/dL) and undetectable IgA. Her length has consistently remained below the 3rd percentile.

When the child was hospitalized at age 4 months, the mother was not acutely ill, but she had chronic non-tender bilateral cervical lymphadenopathy. Her laboratory tests were significant for strongly positive toxoplasmosis serology thought to be secondary to ongoing chronic infection (IgG was 1:16,000; IgG avidity was high, IgM ELISA was 4.1 (normal \< 2.0), and AC/HS ratio of 1,600/3,200). A cervical lymph node biopsy was positive for toxoplasma PCR and she was started on oral pyrimethamine, sulfadiazine, and leucovorin. After 7 months of treatment and moderate improvement in lymphadenopathy, she was switched to suppressive therapy with trimethoprim-sulfamethoxazole (TMP/SMX). When this suppressive regimen was discontinued, the lymphadenopathy worsened. To evaluate for a potential underlying immunodeficiency, both the mother and her daughter were enrolled in NIH protocol 05-I-0213 upon informed consent.

At age 42, the mother was noted to be short (148 cm, \<3rd percentile), and to have generalized lymphadenopathy. A mild persistent EBV viremia (up to 2.58log10) and an intermittent CMV viremia (\< 3.08log10) was observed.

Immunological investigations revealed normal IgG (986 mg/dL) and IgA (69 mg/dL), with elevated IgM (571 mg/dL). The total lymphocyte count was 1,950 cells/μL. Analysis of lymphocyte subsets by flow cytometry demonstrated decreased CD20^+^ CD27^+^ memory B cells (6 cells/μL), increased proportion of CD19^+^ CD10^+^ transitional B cells (36.4% of total B cells), and lack of CD20^+^ CD27^+^ IgM^−^ switched memory B cells. Specific antibody responses to *Streptococcus pneumoniae* were not protective to all serotypes. T-cell studies were significant for markedly reduced number of naïve CD4^+^ CD62L^+^ CD45RA^+^ cells (10 cells/μL) and increased number of central (CD62L^+^ CD45RA^−^, 265 cells/μL) and effector memory (CD62L^−^ CD45RA^−^, 456 cells/μL) CD8^+^ cells.

Whole exome gene sequencing with targeted analysis of 362 PID genes ([Table 1](#T1){ref-type="table"}) identified a heterozygous mutation at an essential donor splice site of *PIK3R1* (NM_181523.2:c.1425+1g\> a), which was confirmed with Sanger sequencing ([Figure 1B](#F1){ref-type="fig"}). The mutation results in the skipping of exon 11, which encodes a part of the inter-SH2 domain of the regulatory p85α subunit, and results in hyperactivation of the PI3K pathway ([@B6]). DNA analysis of the patient\'s daughter demonstrated the same *PIK3R1* c.1425+1g\>a mutation.

###### 

Rare genomic variants identified by whole exome sequencing (WES) and targeted analysis of Primary Immune Deficiency genes in the mother with disseminated Toxoplasmosis.

  **Chromosome**   **Gene**     **Variant**                         **Zygosity**   **Frequency in ExAC**
  ---------------- ------------ ----------------------------------- -------------- -----------------------
  1                *FLG*        NM_002016 c.2365C \>A p.R789S       het            0
  1                *IL12RB2*    NM_001258215 c.778C \>T p.R260W     het            8.24 e-6
  2                *TTC7A*      NM_001288953 c.415+3A \>G           het            0.0007
  3                *TFRC*       NM_001313965 c.67A \>G p.T23A       het            0.0007
  4                *TLR10*      NM_001017388 c.2314C \>T p.R772X    het            0.0016
  5                *SPINK5*     NM_001127698 c.1764T \>G p.I588M    het            0.0028
  5                *ERBB2IP*    NM_001006600 c.3260A \>G p.N1087S   het            0.0008
  5                *PIK3R1*     NM_181523 c.1425+1G \>A             het            0
  6                *TRAF3IP2*   NM_001164281 c.649C \>A p.P217T     het            0.0066
  6                *TNFAIP3*    NM_001270507 c.374C \>T p.A125V     hom            0.0017
  6                *PGM3*       NM_001199918 c.883A \>C p.T295P     het            0
  8                *VPS13B*     NM_017890 c.2825-4T \>A             het            0.0001
  16               *NOD2*       NM_001293557 c.2042G \>A p.R681H    het            0.002
  16               *PLCG2*      NM_002661 c.1712A \>G p.N571S       het            0.0066
  17               *STAT3*      NM_003150 c.1381G \>C p.V461L       het            0.0042
  19               *TYK2*       NM_003331 c.590G \>A p.R197H        het            0.0027

*Synonymous variants and those with a minor allele frequency (MAF) in ExAC \> 0.01 were filtered out. het, heterozygous; hom, homozygous*.

The phosphorylation of Akt is an important downstream event in the activation of the PIK3 pathway. In turn, phosphorylated Akt activates mTOR which phosphorylates S6. Functional studies on the patient\'s CD8^+^ and her daughter\'s CD20^+^ cells confirmed an increased S6 phosphorylation after IL-2 and anti-IgM stimulation ([Figure 1C](#F1){ref-type="fig"}), which suggests hyperactivation of the PI3K-mTOR signaling pathway.

Finally, during admission at the NIH, a PET-scan was performed on the mother, confirming hypermetabolic generalized lymphadenopathy. In order to better define the nature of the lymphoproliferative process, an excisional biopsy of a left cervical lymph node was performed, which revealed an abundance of PD-1^+^ T follicular helper (T~FH~) cells, a striking predominance of IgM^+^ plasma cells (with few IgG^+^ plasma cells), and abnormal germinal centers ([Figure 2](#F2){ref-type="fig"}). The proportion of CD4^+^ CXCR5^+^ CD45RA^−^ CD25^−^ T~FH~ cells was also markedly increased in circulation in the patient as compared to two healthy controls (41.7 vs. 13.7% and 16.6%).

![Lymph node histopathology in the mother with APDS2. **(A)** Hematoxylin & Eosin stained section show an ill-defined secondary follicle with "naked"germinal center; bottom left shows a cluster of monocytoid cells with pale cytoplasm (magnification, 10x). In the inlet, CMV positive cells are identified by immunohistochemistry (magnification, 40x). **(B)** Double immunohistochemisrty staining for CD4^+^ (in brown) and CD8^+^ (in red) T cells (magnification, 10x). **(C)** Immunohistochemistry staining for PD-1 highlights numerous T-follicular helper cells within the germinal centers (stronger expression) as well as in the interfollicular areas (magnification, 10X). **(D--F)** Immunohistochemical stains for CD20^+^ **(D)**, IgM^+^ **(E)**, and IgG^+^ cells **(F)** showing a marked increase of IgM positive plasma cells over IgG (magnification, 4x).](fimmu-10-00077-g0002){#F2}

Upon functional and genetic confirmation of APDS2, we initiated treatment with sirolimus in the mother to inhibit mTOR activation, and added IgG replacement therapy and *Toxoplasma* suppressive therapy with TMP-SMX. This treatment has resulted in improvement of the lymphadenopathy. She remains negative for CMV and EBV viremia by quantitative PCR. Her daughter has been started on TMP-SMX to prevent reactivation of *T. gondii*. At the time of her last follow-up visit (3 years and 3 months of age), she presented with typical immunological hallmarks of the disease, including an increased proportion of central memory CD4^+^ cells (44.1% of total CD4^+^ cells) and of T~EMRA~ CD8^+^ cells (36.1%), along with an elevated proportion of transitional B cells (31.6% of total CD19^+^ cells).

Discussion {#s2}
==========

Immune Deficiencies Reveal Critical Mechanisms Involved in Protection Against *T. Gondii* Infection
---------------------------------------------------------------------------------------------------

*T. gondii* is an obligate intracellular parasite that establishes a relatively benign, life-long infection with only immunocompromised hosts showing signs of clinical disease ([@B12]). Encephalitis and ocular infections are reported in secondary immunodeficiencies due to HIV, chemotherapy and post solid organ or hematopoietic stem cell transplant. Humans and mice act as intermediate hosts and are infected either by ingesting undercooked meat laden with *T. gondii* tissue cysts or by drinking oocyst contaminated water. Tachyzoites released from oocysts or tissue cysts then replicate in intestinal epithelium and myeloid cells can disseminate the infection ([@B13]).

Murine models suggest that different lymphocyte subsets are involved in the acute and chronic phases of parasite control. The acute phase of infection is mediated principally by macrophages, dendritic cells, NK and CD4^+^ cells ([@B14]--[@B16]). Upon engagement of the chemokine receptor 5 (CCR5), Toll-like receptors (TLR) 2 and 11, and the inflammasome sensors NLRP1 and NLRP3 by *Toxoplasma* molecules, antigen presenting cells are activated to produce IL-12 and IL-18 ([@B17]--[@B19]), triggering IFN-γ production by CD4^+^ and NK cells. In turn, IFN-γ upregulates production of reactive oxygen species (ROS) in macrophages thereby inhibiting parasite replication ([@B20], [@B21]). On the other hand, the memory immune response during chronic infection or upon antigenic challenge is driven by IFN-γ producing CD8^+^ T cells ([@B22]).

Identifying human primary immunodeficiencies that are associated with *Toxoplasma* infection is critical for developing an understanding of host defenses against this parasite. A review of the literature yields 24 cases with a diverse set of primary immunodeficiencies that predispose human hosts to severe toxoplasmosis ([Table 2](#T2){ref-type="table"}). The heterogeneity of these diseases suggests that multiple immune system defects may contribute to toxoplasmosis pathogenesis.

###### 

Cases of toxoplasmosis in patients with primary immune deficiencies.

  **Patient \#**   **PID/Age at diagnosis/mutation**                                            **Age at infection/site of *Toxoplasma* infection**          **Diagnostic method of *Toxoplasma* detection**                                                            **Clinical signs/co-morbidities**                                                                                             **Treatment**                                                 **Outcome**                          **References**
  ---------------- ---------------------------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------ ----------------
  1                APDS1/NR/NR                                                                  9 m/NR                                                       NR                                                                                                         NR                                                                                                                            NR                                                            NR                                   ([@B8])
  2                APDS2/NR/NR                                                                  36 y/ocular                                                  NR                                                                                                         NR                                                                                                                            NR                                                            NR                                   ([@B9])
  3                Hyper IgM/2 y/none (absent CD40L on flow)                                    10 y/cerebral                                                *Toxoplasma* tachyzoites seen on brain biopsy                                                              Fever, headache, Babinski, anorexia, papilledema, facial pain                                                                 Pyrimethamine, sulfadiazine, dexamethasone                    Alive                                ([@B23])
  4                CD40L deficiency/41 y/p.R11X                                                 41 y/cerebral                                                *Toxoplasma* tachyzoites and occasional cysts on brain biopsy                                              Recurrent impetigo, Gait disturbance, left sided weakness, sensory disturbance, hemiparesis, sensory loss                     Sulfadiazine, pyrimethamine, clarithromycin, clindamycin      Alive                                ([@B24])
  5                CD40L deficiency/1.4 y/p.C218X                                               2.8 y/cerebral                                               Positive *Toxoplasma* PCR on CSF                                                                           Diarrhea, lethargy, fever, gait disturbance                                                                                   Sulfadiazine, azithromycin, G-CSF                             Deceased                             ([@B25])
  6                CD40L deficiency/5 m/p.V237E                                                 9 y/cerebral                                                 *Toxoplasma* tachyzoites on post mortem brain analysis                                                     Nausea, vomiting, seizures, reduced reflexes, dyskinesia                                                                      Acyclovir, IFN- α (treated for possible viral encephalitis)   Deceased                             ([@B26])
  7                CD40L deficiency/NR/NR                                                       NR/cerebral                                                  NR                                                                                                         NR                                                                                                                            NR                                                            NR                                   ([@B27])
  8                NFKB2 deficiency/2 y/p.R853X                                                 6 y/cerebral and retina                                      Positive *Toxoplasma* PCR on CSF                                                                           Bilateral visual impairment                                                                                                   Sulfadiazine, pyrimethamine, systemic and ocular steroids     Alive                                ([@B28])
  9                IL-12Rβ1 deficiency/37 y/c.\[1745_1746delinsCA\]+\[1483+182_1619-1073del\]   NR/retina                                                    NR                                                                                                         NR                                                                                                                            NR                                                            Alive                                ([@B29])
  10               IL-12Rβ1 deficiency/29 y/p.L77p                                              NR/choroid and retina                                        NR                                                                                                         NR                                                                                                                            NR                                                            Alive                                ([@B29])
  11               IFN-γR1 deficiency/29 y/p.I87T (homozygous)                                  NR/cerebral                                                  NR                                                                                                         NR                                                                                                                            NR                                                            Alive                                ([@B30])
  12               Anti- IFN-γ auto-antibody/65 y/NR                                            63 y/cerebral                                                *Toxoplasma* tbradycoites on brain biopsy                                                                  None reported                                                                                                                 Sulfadiazine, pyrimethamine                                   Alive                                ([@B31])
  13               STAT1 GOF/20 y/c.1154C\>T                                                    2 y/retina (thought to be congential)                        Chorioretinal scar in left eye (thought to be pathognmonic for *Toxoplasma*)                               NR                                                                                                                            NR                                                            Alive                                ([@B32])
  14               TAP1 deficiency/14 y/c.C522T                                                 14 y/ocular                                                  Positive *Toxoplasma* serology (IgM)                                                                       Monoliteral reduction in acuity, cheratitis, anterior uveitis, chorioretinitis, retinal detachment, ultimate loss of vision   Sulfadiazine, pyrimethamine                                   Alive                                ([@B33])
  15               TAP1 deficiency/6 y/c.C1312T                                                 14 y/pneumonitis                                             Positive *Toxoplasma* serology (IgM)                                                                       Granulomatous facial skin lesions, fevers, respiratory distress                                                               Pyrimethamine, sulphadoxin                                    Alive                                ([@B34])
  16               CVID/46 y/NR                                                                 46 y/ocular then disseminated, 50 y/hepatomegaly, 52 y/LAD   46 y-positve Sabian-Feldman dye test; 50 y---positive IFA; 52 y---*Toxoplasma* seen on lymph node biopsy   Uveitis/decreased mitogen T cell responses                                                                                    Sulfadiazine, pyrimethamine, leucovorin                       Alive                                ([@B35])
  17               CVID/NR/NR                                                                   38 y/cerebral                                                *Toxoplasma* cysts on brain biopsy                                                                         Diplopia, hemianopia, hemiparesis, aphasia/PML                                                                                NR                                                            NR                                   ([@B36])
  18               CVID/"adulthood"/NR                                                          52 y/cerebral                                                Positive IHC, pseudocysts on brain biopsy                                                                  Spastic tetraparesis, dysarthria, dysphagia/autoimmune hemolytic (received steroids 4 weeks prior to diagnosis) and LGL       Sulfadiazine, pyrimethamine                                   Alive                                ([@B37])
  19               CVID/19 y/NR                                                                 40 y/cerebral                                                Positive IHC on brain biopsy                                                                               Hemiparesis, loss of nasolabial fold, dysphasia/chronic steroids for necrotizing autoimmune enteritis                         Sulfadiazine, pyrimethamine                                   Alive                                ([@B38])
  20               Good syndrome/43y (thymoma)/NR                                               54 y/cerebral and then disseminated                          Positive *Toxoplasma* PCR on brain biopsy                                                                  Headache, visual disturbance, right sided facial weakness                                                                     Sulfadiazine and pyrimethamine first, then atovaquone added   Alive                                ([@B39])
  21               Mother with Good syndrome (diagnosed 5 years after delivery)/NR/NR           5 m                                                          Positive *Toxoplasma* serology (IgM and IgG)                                                               Nystagmus                                                                                                                                                                                                                        ([@B40])
  22               Nijmegen breakage syndrome/NR/NR                                             15 y/disseminated                                            Tachyzoites on BAL, positive *Toxoplasma* PCR on blood and BAL                                             Acute chest pain/HSCT                                                                                                         Intravenous trimethoprim-sulfamethoxazole, clindamycin        Deceased (39 days post transplant)   ([@B41])
  23               Omenn syndrome/2 m/NR                                                        2 m/NR                                                       Positive *Toxoplasma* serology on blood and CSF (IgM)                                                      NR                                                                                                                            HSCT                                                          NR                                   ([@B42])
  24               ORAI1/NR/NR                                                                  8 m/cerebral                                                 NR                                                                                                         NR/CMV infection                                                                                                              NR                                                            Deceased                             ([@B43])

*NR, not reported*.

Defects of IL-12/IFN-γ Loop
---------------------------

The IL-12/IFN-γ loop facilitates T cell activation and proliferation and intracellular macrophage-mediated parasite killing. Upon T cell receptor (TCR) recognition of a MHC:*Toxoplasma* peptide complex, T lymphocytes are activated and express the CD40 ligand (CD40L) molecule on the cell surface, enabling T cell interaction with macrophages and dendritic cells that constitutively express CD40. CD40L:CD40 signaling activates the non-canonical NF-κB pathway (NFKB2), which increases the cell surface expression of the co-stimulatory molecules CD80/86 ([@B44]). In addition, NFKB2 upregulates IL-12 production in activated macrophages ([@B45]). The ligation of the IL-12R on T lymphocytes by IL-12 leads to IFN-γ release. In turn, ligation of the IFN-γR on macrophages leads to activation of the JAK/STAT pathway, with phosphorylation, dimerization and nuclear translocation of Signal Transducer and Activator of Transcription 1 (STAT1), which helps produce anti-*Toxoplasma* effectors like intracellular ROS.

Review of the literature identified a total of 10 patients with severe *Toxoplasma* infection involving five distinct gene defects along the IL-12/ IFN-γ loop: four cases of CD40L deficiency, one case of heterozygous mutation in *NFKB2*, two cases of IL-12Rβ1 deficiency, one case of STAT1 gain-of-function mutation, and two cases of autosomal recessive IFN-γR1 deficiency ([@B23]--[@B30]). Furthermore, anti-IFN-γ autoantibodies were demonstrated in one patient with severe toxoplasmosis ([@B31]). Interestingly, disruption of IFN-γ signaling (receptor deficiency or auto-antibody production) and CD40L deficiency result in more severe disease, as these defects were associated with *Toxoplasma* encephalitis.

There is evidence that TNF-α may also provide protection against *T. gondii*. In particular, early work by Jack Remington established that regulation of TNF expression determines susceptibility to toxoplasmic encephalitis in mice ([@B46]). Furthermore, Jannsen et al. demonstrated in patients with partial IFN-γR1 deficiency that the addition of TNF-α can limit *T. gondii* replication *in vitro* ([@B47]). The important role of TNF-α in parasite control was also confirmed by the observation that treatment with infliximab may lead to reactivation of cerebral toxoplasmosis ([@B48]).

As mentioned previously, CD8^+^ cells mediate the memory response by recognizing *Toxoplasma* antigens in the context of MHC class I molecules. Transporter associated with antigen processing (TAP) is critical in transporting peptides to the lumen of the endoplasmic reticulum and facilitating peptide loading onto MHC class I molecules. Ocular and pulmonary toxoplasmosis has been reported in two patients with TAP1 deficiency ([@B33], [@B34]). On the other hand, *Tap1*^−/−^ mice succumb to infection faster than *Cd8*^−/−^ mice, and CD4^+^ T cells and NK lymphocytes from *Tap1*^−/−^ mice produce reduced amounts of IFN-γ ([@B49]), indicating that TAP deficiency affects both acute and chronic phases of *Toxoplasma* infection.

Common Variable Immunodeficiency
--------------------------------

Humoral responses are not thought to play an essential role in limiting *Toxoplasma* replication. Three cerebral and one case of disseminated toxoplasmosis in common variable immunodeficiency are published ([@B35]--[@B38]). However, the clinical history and laboratory findings of these cases, characterized by chronic steroid administration for necrotizing autoimmune enteritis, development of large granular leukemia, progressive multifocal leukoencephalopathy and significant reduction in mitogen-induced T cell proliferation, are suggestive of co-existing cellular defects.

Good Syndrome
-------------

Patients with Good Syndrome have thymomas with combined cellular and humoral immunodeficiency and autoimmunity. Cerebral and disseminated *Toxoplasma* infection was reported in one patient with Good syndrome ([@B39]), and *Toxoplasma* reactivation in pregnancy resulting in congenital toxoplasmosis has been described in another patient with the same disease ([@B40]). Further studies are needed to characterize the molecular and cellular mechanisms predisposing to *Toxoplasma* infection in this patient population.

Other T Cell Immunodeficiencies
-------------------------------

Fulminant and fatal reactivation of *T. gondii* infection has been reported early after allogeneic hematopoietic cell transplantation (HCT) in a patient with Nijmegen breakage syndrome ([@B41]). In addition to the underlying immunodeficiency, both the *Toxoplasma* seronegative status of the donor, and use of immunosuppressive therapy pre- and post-transplantation may have contributed to the fatal outcome in this patient. Invasive toxoplasmosis after allogeneic HCT has bene reported in 4--6% of seropositive recipients, with an estimated mortality rate as high as 60--90% ([@B50], [@B51]).

In spite of the severity of T cell immunodeficiency, few cases of toxoplasmosis have bene reported in patients with severe combined immune deficiency (SCID) and related disorders. The rarity of this association is probably related to the fact that infants with SCID die early in life unless immune reconstitution is achieved with HCT. However, cerebral toxoplasmosis has been reported in an infant with Omenn syndrome ([@B42]) and in another infant with severe T cell immunodeficiency due to calcium flux defect ([@B43]).

APDS
----

*Toxoplasma* infection has been previously reported in a 9-month-old infant with APDS1 ([@B8]), and ocular involvement has been described in a 36-year-old patient with APDS2 ([@B9]). *T. gondii* may evade host defense by inducing the activation of the PI3K/AKT signaling pathway which reduces intracellular reactive oxygen species (ROS) through NOX4 suppression ([@B52]) ([Figure 3](#F3){ref-type="fig"}). Active AKT phosphorylates and thereby inactivates the transcription factor FOXO1, thereby preventing p22^phox^ transcription. The resultant decrease of ROS in macrophages leads to reduced activation of AP-1, MAPK, and NF-κB and decreased production of macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine that plays an important role in the immune response to *Toxoplasma* ([@B53]).

![Mechanisms of macrophage-mediated response against *Toxoplasma*, and effects of increase PI3K signaling. **Left:** In immunocompetent hosts, intracellular *Toxoplasma* infection with tachyzoites within parasitophorous vesicles (blue circle) elicits a macrophage response mediated by NOX4 and p22^phox^. Expression of the latter is controlled by the FOXO1 transcription factor. Activation of the NOX4/p22^phox^ complex allows generation of reactive oxygen species (ROS), activation of MAP kinase (MAPK), and NF-κB signaling, and production of the pro-inflammatory macrophage inhibitory factor (MIF). **Right:** In patients with APDS1/2, increased PI3K signaling induces AKT phosphorylation, which in turn mediates phosphorylation of FOXO1, impairing p22^phox^ gene expression (in gray). This causes reduced production of ROS, defective activation of MAPK and NF-κB, and impaired production of MIF (all in gray) in response to *Toxoplasma* infection. Furthermore, the favorable metabolic environment supported by enhanced PI3K activity promotes intracellular replication of *Toxoplasma* tachyzoites.](fimmu-10-00077-g0003){#F3}

Moreover, AKT phosphorylation promotes glycolysis and activation of the amino acid sensor mechanistic target of rapamycin complex 1 (mTORC1), thereby creating an intracellular metabolic environment that is favorable to the intracellular proliferation of *Toxoplasma* parasites, that can utilize micronutrients for their own replication cycle.

Concluding Remarks {#s3}
==================

We have described two patients, a mother and daughter, with an essential donor splice site mutation of *PIK3R1* and disseminated and congenital toxoplasmosis, respectively. Few cases of parasitic infections have been previously reported in patients with APDS, including diarrhea due to *Cryptosporidium parvum* or to *Giardia lamblia* ([@B8]--[@B10]). This is the first time that systemic and severe congenital toxoplasmosis are reported in a mother and child with APDS2, an immune defect that may favor *Toxoplasma* replication. For patients with APDS who are considered for HCT, both donor and recipient *Toxoplasma* serology must be included in the screening work-up. Finally, the identification of severe *Toxoplasma* infection in patients with inborn errors of immunity has helped identify cellular and molecular mechanisms that are critically involved in the immune response against this parasite.
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